NY Times Latest to Mislead Public on New Ivermectin Study • Children’s Health Defense
- The New York Times on Wednesday sent an email to subscribers titled: “Breaking News: Ivermectin failed as a Covid treatment . . .” The Times was referring to a study in the New England Journal of Medicine, covered March 18 by The Wall Street Journal. In both cases, the newspapers failed to provide an accurate critical analysis of the study.
By Madhava Setty, M.D.
*** begin quote ***
Rather than pounding the final nail in the coffin around ivermectin’s utility in treating COVID, the NEJM study raises more questions.
- What would the effect have been if a higher dose shown to be effective were administered?
- What would be the benefit of this medicine in patients with no risk factors?
- How statistically significant would the results have been if more participants were enrolled?
- Why weren’t more participants enrolled as the study progressed given the emerging benefit of the drug and the absence of adverse events?
- Why did the investigators define a primary outcome with such different real-world implications (ER visits vs hospitalizations)?
- With less than 50% of the placebo arm adhering to the study protocol, why were their outcomes included in the analysis?
- What effect did vaccination status have on outcome? If this is the primary means endorsed to prevent hospitalization, why wasn’t vaccination status mentioned as a confounder?
- Did the investigators choose to limit the study as it became clear that an Ivermectin benefit would be too big to ignore?
*** end quote ***
Heaven forbid there would be a real test because it might “embarrass” the experts!